Abivax $920M Raise Funds Solo U.S. Drug Launch

Abivax closes a $920 million equity offering to independently commercialize obefazimod in the U.S. for ulcerative colitis, bypassing a Big Pharma deal and targeting an NDA filing in Q4 2026.

Lead

What Happened

The offering, initially priced at $800 million and subsequently upsized due to strong institutional demand, marks a decisive strategic turn for Abivax. Speaking to CNBC following the close, CEO Marc de Garidel said the capital raised gives the company the infrastructure to launch in the U.S. independently, dissolving months of speculation that Abivax would seek a buyout or licensing deal with a Big Pharma acquirer.

The ABVX stock has climbed to near six-month highs as investors recalibrated the company's standalone commercial prospects. The offering was priced at $125 per ADS.

Clinical Catalyst

The capital raise follows a series of landmark clinical readouts for obefazimod, a first-in-class oral small molecule that modulates post-transcriptional regulation of inflammatory gene expression through the miR-124 pathway — a mechanism distinct from all currently approved therapies for moderate-to-severe ulcerative colitis.

Phase 3 ABTECT induction trials produced a pooled 16.4% placebo-adjusted clinical remission rate at Week 8 across both studies. Maintenance results were more striking: patients on the 50 mg once-daily dose achieved approximately 50–51% clinical remission at Week 44 compared with 10.4% for placebo. Among patients who did not respond to induction therapy — historically one of the hardest-to-treat populations in inflammatory bowel disease — the 50 mg arm still delivered 37.2% clinical remission and 61.5% clinical response at Week 44.

Long-term integrated safety data spanning 1,704 patient-years showed malignancy and non-melanoma skin cancer rates consistent with background ulcerative colitis rates, resolving a cancer-signal concern that had overhung the ABVX stock earlier in the year.

Market Reaction

The ABVX share price surged following both the Phase 3 data release in late June and the offering close in July. Multiple Wall Street firms updated their views after the clinical results: BTIG raised its price target to $175 and maintained a Buy rating, while Jefferies upgraded the stock to Buy with a $158 target. The oversubscription of the equity offering itself signals broad institutional conviction in the biotech drug launch thesis.

Strategic Context

The independent path is notable within the pharmaceutical industry landscape. French biotechs of Abivax's scale have historically required Big Pharma partnerships to fund U.S. commercialization, given the costs of building a sales infrastructure and navigating FDA approval. The $920 million raise changes that calculus materially, granting Abivax negotiating leverage it did not previously hold and eliminating the dilutive economics of a co-promotion or licensing agreement.

Obefazimod's once-daily oral profile positions it to compete directly with injectable biologics — including TNF inhibitors and IL-12/23 antagonists — as well as the JAK inhibitor class, in a market where patient preference for oral administration has grown steadily.

Regulatory Path

Abivax has scheduled a pre-NDA meeting with the U.S. Food and Drug Administration for late July 2026. The session will allow the company to align with regulators on the submission package before filing the full New Drug Application in the fourth quarter of 2026. If the timeline holds and the FDA grants standard review, a regulatory decision could arrive in late 2027.

Outlook

With $874 million in net proceeds, a clean safety profile, and competitive Phase 3 efficacy data in hand, Abivax enters its most consequential commercial phase as a standalone entity. The pre-NDA FDA meeting in late July will be the first major test of whether regulators share the company's confidence in the submission package. Approval would mark one of the few recent instances of a mid-sized European biotech executing a full independent drug launch in the U.S. market — a model the broader pharmaceutical industry will be watching closely.

Biotech }}